GlassScriptPhysician profile
Sarah Lynch
NPI 1669013595
$5,204.28
in general payments reported to CMS, 2019-2025
20 companies · $329 in 2025
The $329 reported for 2025 was more than what a typical Psychiatric/Mental Health (Nurse Practitioner) provider received nationally (typical 2025 total: $257).
See the full distribution for Psychiatric/Mental Health (Nurse Practitioner)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $1,071 · 2022: $1,233 · 2023: $1,184 · 2024: $1,388 · 2025: $329.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,901.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,901.09 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $807.93 | 2021-2024 | |
| Teva Pharmaceuticals USA, INC. | $629.05 | 2022-2025 | Uzedy, Austedo, Austedo Xr |
| Otsuka America Pharmaceutical, INC. | $462.70 | 2021-2024 | Rexulti, Nuedexta, Abilify Maintena |
| Janssen Pharmaceuticals, INC | $404.00 | 2021-2024 | Invega Sustenna, Invega Trinza, Spravato |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $376.62 | 2021-2025 | Caplyta |
| Sunovion Pharmaceuticals INC. | $372.28 | 2021-2022 | |
| Vanda Pharmaceuticals INC. | $365.80 | 2021-2025 | Fanapt, Hetlioz |
| Alkermes, INC. | $331.18 | 2021-2025 | Aristada, Lybalvi |
| Lundbeck LLC | $313.45 | 2021-2025 | Rexulti |
| Neurocrine Biosciences, INC. | $288.09 | 2021-2025 | Ingrezza |
| Axsome Therapeutics, INC. | $230.02 | 2022-2025 | Auvelity |
| Takeda Pharmaceuticals U.S.A., INC. | $161.04 | 2021-2023 | Trintellix |
| Idorsia Pharmaceuticals US INC | $114.76 | 2022-2024 | Quviviq |
| Bausch Health US, LLC | $97.35 | 2021-2024 | Aplenzin, Wellbutrin |
| Noven Therapeutics, LLC | $92.51 | 2024 | Secuado, Xelstrym |
Show all 20 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Almatica Pharma LLC | $63.58 | 2022-2025 | Loreev Xr |
| Indivior INC. | $28.39 | 2022 | |
| E.R. Squibb & Sons, L.L.C. | $28.31 | 2024 | Cobenfy |
| Merck Sharp & Dohme LLC | $19.34 | 2022 | |
| Jazz Pharmaceuticals INC. | $17.88 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Sarah Lynch listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.